The Oxford Handbook of the Economics of the Biopharmaceutical Industry
The Economics of Vaccines
Publication
, Chapter
Sloan, FA
September 18, 2012
This article discusses preventive vaccines, focusing on features that differentiate these vaccines from other biopharmaceuticals. The external costs of infectious diseases imply external benefits from effective vaccines, and this has motivated public mandates, purchasing, and subsidies to demand for vaccines in most countries and government subsidies to supply for particular products, such as Project Bioshield in the United States. The article reviews these issues and then discusses factors that have contributed to the existence of few or sole suppliers of individual vaccines in the United States and possible policy responses.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Sloan, F. A. (2012). The Economics of Vaccines. In The Oxford Handbook of the Economics of the Biopharmaceutical Industry. https://doi.org/10.1093/oxfordhb/9780199742998.013.0017
Sloan, F. A. “The Economics of Vaccines.” In The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 2012. https://doi.org/10.1093/oxfordhb/9780199742998.013.0017.
Sloan FA. The Economics of Vaccines. In: The Oxford Handbook of the Economics of the Biopharmaceutical Industry. 2012.
Sloan, F. A. “The Economics of Vaccines.” The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 2012. Scopus, doi:10.1093/oxfordhb/9780199742998.013.0017.
Sloan FA. The Economics of Vaccines. The Oxford Handbook of the Economics of the Biopharmaceutical Industry. 2012.